SCHEMBL3243689

SCHEMBL3243689

O=C(NCCc1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.68
POLB P06746 1/20 0.68
HDAC3 O15379 1/20 0.66
HDAC4 P56524 1/20 0.66
HDAC1 Q13547 1/20 0.66
HDAC7 Q8WUI4 1/20 0.66
HDAC2 Q92769 1/20 0.66
HDAC10 Q969S8 1/20 0.66
HDAC11 Q96DB2 1/20 0.66
HDAC8 Q9BY41 1/20 0.66
HDAC6 Q9UBN7 1/20 0.66
HDAC9 Q9UKV0 1/20 0.66
HDAC5 Q9UQL6 1/20 0.66
RAB9A P51151 5/20 0.64
NPC1 O15118 4/20 0.64
MLYCD O95822 2/20 0.61
TP53BP1 Q12888 1/20 0.61
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HPGD P15428 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233030 0.92 NAMPT (0.64) ALDH1A1POLBHDAC3HDAC4HDAC1
SCHEMBL11368205 0.90 POLB (0.62) ALDH1A1POLBHDAC3HDAC4HDAC1
SCHEMBL11481078 0.90 ALDH1A1 (0.62) ALDH1A1POLBHDAC3HDAC4HDAC1
SCHEMBL17554073 0.87 RXFP1 (0.65) ALDH1A1RAB9ALMNA
SCHEMBL23447718 0.86 LMNA (0.74) ALDH1A1POLBHDAC2HDAC8HDAC6
SCHEMBL3062674 0.85 MLYCD (0.76) HDAC4HDAC2HDAC8HDAC6RAB9A
SCHEMBL5969299 0.85 ESRRG (0.73) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL26491384 0.83 LMNA (0.65) ALDH1A1POLBHDAC3HDAC1RAB9A
SCHEMBL3514277 0.82 POLB (0.76) ALDH1A1POLBHDAC3HDAC1HDAC2
SCHEMBL3514281 0.82 POLB (0.76) ALDH1A1POLBHDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292269-A1 BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS, INC. (CA) 2010-11-18 US disclosed
US-7745477-B2 Heteroaryl and benzyl amide compounds HOFFMAN-LA ROCHE INC. (US) 2010-06-29 US disclosed
US-20070185058-A1 Heteroaryl and benzyl amide compounds HOFFMANN-LA ROCHE INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185058-A1 Heteroaryl and benzyl amide compounds CYP1B1, CYP4B1, ABCG2 ALDH1A1 986/4885POLB 1245/4885HDAC3 140/4885
US-20100292269-A1 BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC3, BIRC2 ALDH1A1 3348/4885POLB 522/4885HDAC3 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.